Bruker (NASDAQ:BRKR) Given New $45.00 Price Target at Barclays

Bruker (NASDAQ:BRKR) had its price objective decreased by Barclays from $50.00 to $45.00 in a research report released on Tuesday morning,Benzinga reports. Barclays currently has an overweight rating on the medical research company’s stock.

BRKR has been the topic of several other research reports. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a report on Friday, March 27th. The Goldman Sachs Group decreased their price objective on Bruker from $40.00 to $35.00 and set a “sell” rating on the stock in a report on Friday, February 13th. UBS Group restated a “neutral” rating and set a $49.00 price objective on shares of Bruker in a report on Friday, February 13th. Guggenheim decreased their price objective on Bruker from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Finally, JPMorgan Chase & Co. raised their price objective on Bruker from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $49.38.

Bruker Price Performance

BRKR stock opened at $39.90 on Tuesday. Bruker has a 52-week low of $28.53 and a 52-week high of $56.22. The stock’s fifty day simple moving average is $37.58 and its 200-day simple moving average is $41.71. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75. The stock has a market capitalization of $6.07 billion, a price-to-earnings ratio of -266.00, a price-to-earnings-growth ratio of 2.34 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.06). Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The business had revenue of $977.20 million for the quarter, compared to analyst estimates of $964.61 million. During the same quarter last year, the business earned $0.76 EPS. Bruker’s revenue for the quarter was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts expect that Bruker will post 2.69 EPS for the current year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 23rd were given a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Monday, March 23rd. Bruker’s dividend payout ratio (DPR) is -133.33%.

Insider Buying and Selling at Bruker

In related news, VP Mark Munch sold 2,000 shares of the stock in a transaction on Friday, March 13th. The stock was sold at an average price of $35.44, for a total value of $70,880.00. Following the transaction, the vice president directly owned 128,443 shares of the company’s stock, valued at approximately $4,552,019.92. This trade represents a 1.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 27.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Los Angeles Capital Management LLC purchased a new position in shares of Bruker in the 4th quarter worth $26,000. Allworth Financial LP raised its position in Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares during the period. Parallel Advisors LLC raised its position in Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares during the period. Spire Wealth Management raised its position in Bruker by 85.3% in the third quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 665 shares during the period. Finally, Summit Securities Group LLC purchased a new position in Bruker in the fourth quarter valued at about $50,000. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.